Advancing the Care of Patients With Type 2 Diabetes and Chronic Kidney Disease: Role of the Glucagon-Like Peptide-1 Receptor Agonists

To participate in this activity, please:

Log in Sign Up

The care of patients with type 2 diabetes and chronic kidney disease requires a multidisciplinary approach; hence, this activity takes a multidisciplinary approach to educate clinicians of various disciplines. Nephrologist and clinical trialist George Bakris, MD, reviews the burden of diabetic kidney disease (DKD) and provides guideline recommendations to properly screen and prevent cardiovascular disease events in patients with DKD. Fellow clinical trialist and diabetes expert John Buse, MD, PhD, discusses the pharmacology and prescribing considerations of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and highlights this class while reviewing new consensus reports. Dr. Buse teams up with Dr. Bakris to discuss the cardiorenal benefits of GLP-1 RAs evidenced by cardiovascular outcomes trials and recent meta-analyses. Primary care and internal medicine specialist John Anderson, MD, joins Drs. Bakris and Buse to lead the discussion of 2 cases of patients with DKD. Dr. Anderson concludes by discussing the importance of multidisciplinary management in optimizing care for our patients with type 2 diabetes and chronic kidney disease.

This program is also available as a podcast. You may download it here:https://anchor.fm/t2d-ckd

Course Credit:

1.5 ACPE Contact Hours
1.5 AMA PRA Category 1 CreditsTM
1.5 ANCC Contact Hours
1.5 CA-BRN Contact Hours
1 Pharmacology Hour

Dates:

Opens: 2023-02-06
Closes: 2024-02-06

Target Audience:

This activity was developed for nephrologists, endocrinologists, family physicians, physician assistants, nurse practitioners, pharmacists and other clinicians interested in the prevention and management of nephropathy in patients with type 2 diabetes.

This activity is supported by an independent educational grant from Novo Nordisk Inc.

Accreditation Information

Accreditation

In support of improving patient care, Annenberg Center for Health Sciences at Eisenhower (Annenberg Center) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The Annenberg Center for Health Sciences at Eisenhower designates this enduring activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Annenberg Center for Health Sciences at Eisenhower designates this knowledge-based activity for a maximum of 1.5 hours. Credit will be provided to NABP CPE Monitor within 60 days after the activity completion.

Annenberg Center for Health Sciences at Eisenhower designates this enduring activity for a maximum of 1.5 contact hours, including 1 pharmacology hour.

Provider is approved by the California Board of Registered Nursing, Provider #13664, for 1.5 contact hours.
To receive credit for education contact hours outside of the state of California, please check with your state board of registered nursing for reciprocity.

Additional Content Planners

Eugene Cullen, MD (Peer Reviewer)
No significant relationships to disclose.

Amber Lambert, MSN, FNP-C, DNP (Nurse Reviewer)
No significant relationships to disclose.

Chandler Schexnayder, PharmD, BCPS, CDCES, BCACP (Medical Writer)
No significant relationships to disclose.

Annenberg Center for Health Sciences

Staff at the Annenberg Center for Health Sciences at Eisenhower have no relevant financial relationships to disclose.

All of the financial relationships listed for these individuals have been mitigated.

    Presenting Faculty

  • John E. Anderson, MD

    Internal Medicine and Diabetes
    The Frist Clinic
    Nashville, Tennessee

  • George Bakris, MD

    Professor of Medicine
    Director, American Heart Association Comprehensive Hypertension Center
    University of Chicago Medicine
    Chicago, Illinois

  • John B. Buse, MD, PhD

    Verne S. Caviness Distinguished Professor
    Director, Diabetes Center
    Director, NC Translational and Clinical Sciences Institute
    Senior Associate Dean, Clinical Research
    University of North Carolina School of Medicine
    Chapel Hill, North Carolina

Learning Objectives

  • Describe the impact of diabetes on the progression of chronic kidney disease and cardiovascular disease.
  • Differentiate glycemic and non-glycemic effects among glucagon-like peptide-1 receptor agonists (GLP-1 RAs).
  • Describe the efficacy, safety, and role of GLP-1 RAs in the treatment of adults with type 2 diabetes, chronic kidney disease, and established atherosclerotic cardiovascular disease.
  • Initiate evidence-based GLP-1 RA therapy in patients with T2D and CKD.

Faculty Disclosures

John E. Anderson, MD

Consultant: Abbott Diabetes, AlfaSigma, AstraZeneca, Bayer, Boerhinger Ingelheim, Eli Lilly, Intuity Medical, Novo Nordisk, Sanofi

Speaker: AstraZeneca, Bayer, Eli Lilly, Novo Nordisk, Sanofi


George Bakris, MD

Consultant: Alnylam, AstraZeneca, Bayer, DiaMedica Therapeutics, inRegen, Ionis, KBP Biosciences, Novo Nordisk

Steering Committee: Alnylam, AstraZeneca, Bayer, DiaMedica Therapeutics, inRegen, Ionis, KBP Biosciences, Novo Nordisk


John B. Buse, MD, PhD

Consultant: Alkahest, Altimmune, Anji, AstraZeneca, Bayer, Biomea Fusion, Boehringer Ingelheim, CeQur, Cirius Therapeutics, Eli Lilly, GentiBio, Glycadia, Glyscend, Janssen, MannKind, Mellitus Health, Moderna, Pendulum Therapeutics, Praetego, Sanofi, Stability Health, Terns, Valo, Zealand Pharma

Stock/Stock Options: Glyscend, Mellitus Health, Pendulum Therapeutics, PhaseBio, Praetego, Stability Health